{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:22:59Z","timestamp":1783527779703,"version":"3.55.0"},"reference-count":64,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dx Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Ovarian cancer (OC) is a leading cause of cancer-related mortality in women, largely driven by late-stage diagnosis. Five-year survival is just 30% for advanced-stage (III-IV) disease but exceeds 90% for early-stage disease, underscoring the critical need for effective early detection tools. Current standard-of-care biomarkers show limited sensitivity for early-stage OC and lack specificity in symptomatic populations. Most biomarker studies in OC serum evaluate single molecular classes or compare OC to healthy controls, limiting understanding of coordinated biological alterations in circulating proteins, lipids, and metabolites in clinically relevant populations. Methods: We performed integrated multi-omics profiling of serum from a retrospective, case\u2013control cohort of women presenting with vague abdominal symptoms (VAS), including early- and late-stage OC, borderline tumors, benign gynecologic conditions including adnexal masses, GI disorders, and healthy controls. Protein biomarkers were quantified by ELISA, lipidomic profiling was performed by untargeted LC-MS, and ganglioside and metabolomic profiling were performed by semi-targeted LC-MS with metabolite annotation performed against a curated reference library. Results: Consistent with known limitations for early-stage OC detection, CA125 and HE4 levels overlapped substantially with benign gynecologic conditions. Additional proteins also showed limited separation in their expression between early-stage OC and symptomatic controls. In contrast, OC showed unique lipid and metabolite profiles: phospholipids and glycerolipids were decreased, and sphingolipid composition was altered. Borderline and benign conditions exhibited lipid profiles that fall between healthy and OC groups, suggesting a continuum of metabolic changes rather than distinct states between OC and non-OC controls. Sphingolipid alterations included changes in ceramides and sphingomyelins, along with broader dysregulation of ganglioside profiles, including an elevated GD2;O2-to-GD1;O2 ratio. Metabolic profiling showed decreased amino acids and enriched cysteine metabolism in OC, consistent with altered redox balance, along with changes in fatty acids and acyl-carnitines, suggesting altered lipid metabolism and inflammatory mechanisms. Lower levels of glycolytic and TCA cycle intermediates in OC suggested altered mitochondrial metabolism and energetic reprogramming. Pairwise comparisons revealed a gradient of significance between groups, with differences between OC and healthy controls across lipid classes (LPC, PC, PE, TG, SM), gangliosides (GD1, GD2, GD2\/GD1 ratio), and metabolites (amino acids, Cys\/CySS, TCA cycle); borderlines occupied an intermediate space. Integration of these datasets revealed coordinated cross-omics relationships, identifying links between metabolite, lipid, and protein features. Together, these connections highlight structured, system-level alterations related to lipid remodeling, redox balance, immune signaling, and energy metabolism that no single modality would have revealed in isolation. Conclusions: This study presents an integrated analysis of the lipidome, gangliosome, metabolome, and protein biomarkers within a single clinically relevant symptomatic cohort enriched with multiple stages and subtypes of OC. This multi-omics framework demonstrates that molecular alterations in OC are biologically interconnected across molecular classes. While these findings are discovery-based and require independent validation prior to clinical application, they support the development of clinically deployable multi-omics biomarker strategies for early detection and potential pathways for therapeutic intervention.<\/jats:p>","DOI":"10.3390\/diagnostics16142143","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:40:09Z","timestamp":1783525209000},"page":"2143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-Omics Profiling in a Symptomatic Cohort Identifies Coordinated Biomarker Signatures in Ovarian Cancer Serum"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3000-083X","authenticated-orcid":false,"given":"Rachel","family":"Culp-Hill","sequence":"first","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Nichols","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Kilkenny","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattie","family":"Goldberg","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-8137","authenticated-orcid":false,"given":"Enkhtuya","family":"Radnaa","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2337-6244","authenticated-orcid":false,"given":"Maria","family":"Wong","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Zapata","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Denver, CO 80217, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5809-5271","authenticated-orcid":false,"given":"Benjamin G.","family":"Bitler","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Denver, CO 80217, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jeter","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuna S.","family":"Fa","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-4736","authenticated-orcid":false,"given":"Kim","family":"Ekroos","sequence":"additional","affiliation":[{"name":"Lipidomics Consulting Ltd., 02230 Esbo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"McElhinny","sequence":"additional","affiliation":[{"name":"AOA Dx, Denver, CO 80221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","first-page":"102530","article-title":"Ovarian Cancer: A Review","volume":"7","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.xcrm.2025.102530","article-title":"zAvatar-Test\u2014A Functional Precision Model to Personalize Ovarian Cancer Treatments: Results from a Co-Clinical Study","volume":"7","author":"Estrada","year":"2026","journal-title":"Cell Rep. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Harter","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_4","unstructured":"Reid, F. (2018). The Everywoman Study Summary Report, World Ovarian Cancer Coalition."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.31557\/apjcb.2024.9.1.81-85","article-title":"Biomarkers for Early Detection of Ovarian Cancer: A Review","volume":"9","author":"Bindu","year":"2024","journal-title":"Asian Pac. J. Cancer Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, R., Siu, M.K.Y., Ngan, H.Y.S., Chan, K.K.L., Zhang, R., Siu, M.K.Y., Ngan, H.Y.S., and Chan, K.K.L. (2022). Molecular Biomarkers for the Early Detection of Ovarian Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231912041"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00216-021-03583-2","article-title":"Mass Spectrometry Based High-Throughput Bioanalysis of Low Molecular Weight Compounds: Are We Ready to Support Personalized Medicine?","volume":"414","author":"Hopfgartner","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of Cancer\u2014Then and Now, and Beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mco2.27","article-title":"Lipid Metabolism in Cancer Progression and Therapeutic Strategies","volume":"2","author":"Fu","year":"2020","journal-title":"MedComm"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20180045","DOI":"10.1515\/hmbci-2018-0045","article-title":"Novel Strategies for Clinical Investigation and Biomarker Discovery: A Guide to Applied Metabolomics","volume":"38","author":"Carneiro","year":"2019","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2012.11.022","article-title":"Ovarian Malignancy Risk Stratification of the Adnexal Mass Using a Multivariate Index Assay","volume":"128","author":"Bristow","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ijgo.14733","article-title":"A Reflex Testing Protocol Using Two Multivariate Index Assays Improves the Risk Assessment for Ovarian Cancer in Patients with an Adnexal Mass","volume":"162","author":"Fritsche","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tzelepi, V., Gika, H., Begou, O., and Timotheadou, E. (2023). The Contribution of Lipidomics in Ovarian Cancer Management: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202308.0256.v1"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Vidoni, C., Ferraresi, A., Vallino, L., Salwa, A., Ha, J.H., Seca, C., Garavaglia, B., Dhanasekaran, D.N., and Isidoro, C. (2023). Glycolysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021723"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"0351","DOI":"10.34133\/research.0351","article-title":"The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy","volume":"7","author":"Wu","year":"2024","journal-title":"Research"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Horala, A., Plewa, S., Derezinski, P., Klupczynska, A., Matysiak, J., Nowak-Markwitz, E., and Kokot, Z.J. (2021). Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors\u2014A Comparative Study with Review of the Literature. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18042167"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1158\/2767-9764.CRC-23-0138","article-title":"Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer","volume":"3","author":"Katoh","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Galan, A., Papaluca, A., Nejatie, A., Matanes, E., Brahimi, F., Tong, W., Yaseen, I.H., Yasmeen, A., Carmona, E., and Oros Klein, K. (2023). GD2 and GD3 Gangliosides as Diagnostic Biomarkers for All Stages and Subtypes of Epithelial Ovarian Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1134763"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/2767-9764.CRC-25-0140","article-title":"Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population","volume":"5","author":"Giles","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Law, R.A., Giles, B.M., Culp-Hill, R., Radnaa, E., Goldberg, M., Nichols, C.M., Wong, M., Hansen, C., Hill, C., and Eurich, K. (2025). Clinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection. Diagnostics, 15.","DOI":"10.3390\/diagnostics15172225"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nbt.2377","article-title":"A Cross-Platform Toolkit for Mass Spectrometry and Proteomics","volume":"30","author":"Chambers","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00726-015-2019-9","article-title":"Three-Minute Method for Amino Acid Analysis by UHPLC and High-Resolution Quadrupole Orbitrap Mass Spectrometry","volume":"47","author":"Nemkov","year":"2015","journal-title":"Amino Acids"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/nar\/27.1.29","article-title":"KEGG: Kyoto Encyclopedia of Genes and Genomes","volume":"27","author":"Ogata","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"W398","DOI":"10.1093\/nar\/gkae253","article-title":"MetaboAnalyst 6.0: Towards a Unified Platform for Metabolomics Data Processing, Analysis and Interpretation","volume":"52","author":"Pang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F.O., Narod, S.A., and Akbari, M.R. (2020). CA125 and Ovarian Cancer: A Comprehensive Review. Cancers, 12.","DOI":"10.3390\/cancers12123730"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 Levels Are Less Frequently Elevated than CA125 in Women with Benign Gynecologic Disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2011.06.002","article-title":"Proteomic Biomarkers Apolipoprotein A1, Truncated Transthyretin and Connective Tissue Activating Protein III Enhance the Sensitivity of CA125 for Detecting Early Stage Epithelial Ovarian Cancer","volume":"122","author":"Clarke","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12967-016-0832-x","article-title":"Human Epithelial-Type Ovarian Tumour Marker Beta-2-Microglobulin Is Regulated by the TGF-\u03b2 Signaling Pathway","volume":"14","author":"Sun","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.clinbiochem.2013.03.010","article-title":"Folate-Receptor 1 (FOLR1) Protein Is Elevated in the Serum of Ovarian Cancer Patients","volume":"46","author":"Leung","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00262-011-1010-x","article-title":"Soluble MUC1 and Serum MUC1-Specific Antibodies Are Potential Prognostic Biomarkers for Platinum-Resistant Ovarian Cancer","volume":"60","author":"Budiu","year":"2011","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1471-0528.2004.00142.x","article-title":"Increased Levels of Gangliosides in the Plasma and Ascitic Fluid of Patients with Advanced Ovarian Cancer","volume":"111","author":"Santin","year":"2004","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12770","DOI":"10.1074\/jbc.273.21.12770","article-title":"A Family of Human Beta3-Galactosyltransferases. Characterization of Four Members of a UDP-Galactose:Beta-N-Acetyl-Glucosamine\/Beta-Nacetyl-Galactosamine Beta-1,3-Galactosyltransferase Family","volume":"273","author":"Amado","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","article-title":"B3GALT4 Remodels the Tumor Microenvironment through GD2-Mediated Lipid Raft Formation and the c-Met\/AKT\/mTOR\/IRF-1 Axis in Neuroblastoma","volume":"41","author":"Sha","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic Reprogramming and Epigenetic Modifications in Cancer: From the Impacts and Mechanisms to the Treatment Potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of Fatty Acid Metabolism in Cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Xia, Q., Gao, W., Yang, J., Xing, Z., and Ji, Z. (2024). The Deregulation of Arachidonic Acid Metabolism in Ovarian Cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1381894"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1096\/fj.14-257352","article-title":"MUC16: Molecular Analysis and Its Functional Implications in Benign and Malignant Conditions","volume":"28","author":"Haridas","year":"2014","journal-title":"FASEB J."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chen, X., Sandrine, I.K., Yang, M., Tu, J., and Yuan, X. (2024). MUC1 and MUC16: Critical for Immune Modulation in Cancer Therapeutics. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1356913"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.eclinm.2023.102041","article-title":"A Panel of Seven Protein Tumour Markers for Effective and Affordable Multi-Cancer Early Detection by Artificial Intelligence: A Large-Scale and Multicentre Case-Control Study","volume":"61","author":"Luan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ol.2020.11629","article-title":"Comparison of Risk of Ovarian Malignancy Algorithm and Cancer Antigen 125 to Discriminate between Benign Ovarian Tumor and Early-Stage Ovarian Cancer According to Imaging Tumor Subtypes","volume":"20","author":"Lee","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17588359241233225","DOI":"10.1177\/17588359241233225","article-title":"Diagnostic Biomarkers in Ovarian Cancer: Advances beyond CA125 and HE4","volume":"16","author":"Ghose","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"639.e1","DOI":"10.1016\/j.ajog.2008.12.042","article-title":"Validation of Serum Biomarkers for Detection of Early-Stage Ovarian Cancer","volume":"200","author":"Nosov","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/s41417-022-00503-z","article-title":"CpG-Binding Protein CFP1 Promotes Ovarian Cancer Cell Proliferation by Regulating BST2 Transcription","volume":"29","author":"Yang","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jogoh.2018.03.010","article-title":"Evaluation of HE4 and TTR for Diagnosis of Ovarian Cancer: Comparison with CA-125","volume":"47","author":"Zheng","year":"2018","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1158\/1055-9965.EPI-20-1057","article-title":"Biomarkers and Strategies for Early Detection of Ovarian Cancer","volume":"29","author":"Bast","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_49","first-page":"171","article-title":"Biomarkers for Early Detection of Ovarian Cancer","volume":"9","author":"Nguyen","year":"2013","journal-title":"Women\u2019s Health"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12943-025-02243-8","article-title":"Inflammation in Cancer: Therapeutic Opportunities from New Insights","volume":"24","author":"Xie","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12199-018-0740-1","article-title":"Inflammation and Cancer","volume":"23","author":"Murata","year":"2018","journal-title":"Environ. Health Prev. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Turizo-Smith, A.D., C\u00f3rdoba-Hernandez, S., Mej\u00eda-Guarnizo, L.V., Monroy-Camacho, P.S., and Rodr\u00edguez-Garc\u00eda, J.A. (2024). Inflammation and Cancer: Friend or Foe?. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1385479"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3892\/etm.2020.9594","article-title":"Inflammatory Signals Induce MUC16 Expression in Ovarian Cancer Cells via NF-\u03baB Activation","volume":"21","author":"Liu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zannoni, G.F., Santoro, A., d\u2019Amati, A., D\u2019Alessandris, N., Scaglione, G., Urtueta, B.P., Valente, M., Narducci, N., Addante, F., and Spadola, S. (2025). Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115222"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mai, J., Wu, L., Yang, L., Sun, T., Liu, X., Yin, R., Jiang, Y., Li, J., and Li, Q. (2023). Therapeutic Strategies Targeting Folate Receptor \u03b1 for Ovarian Cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1254532"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: A Promising Pan-Cancer Therapeutic Target","volume":"9","author":"Grewal","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18156","DOI":"10.1038\/s41598-021-97433-x","article-title":"Quantitative Global Lipidomics Analysis of Patients with Ovarian Cancer versus Benign Adnexal Mass","volume":"11","author":"Buas","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1055-9965.EPI-23-1293","article-title":"Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women","volume":"33","author":"Sah","year":"2024","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2767-9764.CRC-23-0513","article-title":"Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression","volume":"4","author":"Crump","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-19-1057","article-title":"Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression","volume":"18","author":"Sawyer","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1017\/S0007114523002490","article-title":"Time-Resolved Concentrations of Serum Amino Acids, One-Carbon Metabolites and B-Vitamin Biomarkers during the Postprandial and Fasting State: The Postprandial Metabolism in Healthy Young Adults (PoMet) Study","volume":"131","author":"Anfinsen","year":"2023","journal-title":"Br. J. Nutr."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Al-Sulaiti, H., Almaliti, J., Naman, C.B., Thani, A.A.A., and Yassine, H.M. (2023). Metabolomics Approaches for the Diagnosis, Treatment, and Better Disease Management of Viral Infections. Metabolites, 13.","DOI":"10.3390\/metabo13080948"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/clinem\/dgac112","article-title":"Fluctuations in Metabolites and Bone Markers Across the Menstrual Cycle in Eumenorrheic Women and Oral Contraceptive Users","volume":"107","author":"He","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kim, K., Mall, C., Taylor, S.L., Hitchcock, S., Zhang, C., Wettersten, H.I., Jones, A.D., Chapman, A., and Weiss, R.H. (2014). Mealtime, Temporal, and Daily Variability of the Human Urinary and Plasma Metabolomes in a Tightly Controlled Environment. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086223"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/14\/2143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:56:53Z","timestamp":1783526213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/14\/2143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":64,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16142143"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16142143","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}